Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe Pharmaceutical TechnologyLilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.OncologyRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaceutical Technology Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults. Oncology Read full story Post navigation Previous: Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and ZepboundNext: Ipsen charts $1.75bn course for Kartos acquisition Related Stories Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026 Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026
